Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer

Q4 Medicine

Revista Espanola de Patologia Pub Date : 2023-01-01 DOI:10.1016/j.patol.2022.06.004

Ruth Vera , Carolina Ibarrola-de Andrés , Jorge Adeva , Judith Pérez-Rojas , Pilar García-Alfonso , Yolanda Rodríguez-Gil , Teresa Macarulla , Teresa Serrano-Piñol , Rebeca Mondéjar , Beatriz Madrigal-Rubiales

{"title":"Expert consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology on the determination of biomarkers in pancreatic and biliary tract cancer","authors":"Ruth Vera , Carolina Ibarrola-de Andrés , Jorge Adeva , Judith Pérez-Rojas , Pilar García-Alfonso , Yolanda Rodríguez-Gil , Teresa Macarulla , Teresa Serrano-Piñol , Rebeca Mondéjar , Beatriz Madrigal-Rubiales","doi":"10.1016/j.patol.2022.06.004","DOIUrl":null,"url":null,"abstract":"<div>Pancreatic cancer and biliary tract cancer have a poor prognosis. In recent years, the development of new diagnostic techniques has enabled the identification of the main genetic alterations involved in the development of these tumours. Multiple studies have assessed the ability to predict response to treatment of certain biomarkers, such as BRCA in pancreatic cancer, IDH1 or FGFR2 in biliary tract cancer and microsatellite instability or NTRK fusions in an agnostic tumour fashion.In this consensus, a group of experts selected by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) reviewed the role played by these mutations in the process of carcinogenesis and their clinical implications. Based on their results, a series of recommendations are made to optimize the determination of these biomarkers and thus help standardize the diagnosis and treatment of these tumours.</div>","PeriodicalId":39194,"journal":{"name":"Revista Espanola de Patologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista Espanola de Patologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1699885522000447","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Pancreatic cancer and biliary tract cancer have a poor prognosis. In recent years, the development of new diagnostic techniques has enabled the identification of the main genetic alterations involved in the development of these tumours. Multiple studies have assessed the ability to predict response to treatment of certain biomarkers, such as BRCA in pancreatic cancer, IDH1 or FGFR2 in biliary tract cancer and microsatellite instability or NTRK fusions in an agnostic tumour fashion.

In this consensus, a group of experts selected by the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP) reviewed the role played by these mutations in the process of carcinogenesis and their clinical implications. Based on their results, a series of recommendations are made to optimize the determination of these biomarkers and thus help standardize the diagnosis and treatment of these tumours.

查看原文本刊更多论文

西班牙病理学会和西班牙肿瘤医学学会关于胰腺癌和胆道癌生物标志物测定的专家共识

癌症和癌症胆道预后不良。近年来，新诊断技术的发展使得能够识别这些肿瘤发展过程中涉及的主要基因改变。多项研究评估了预测某些生物标志物治疗反应的能力，如胰腺癌症中的BRCA、癌症胆道中的IDH1或FGFR2以及以不可知肿瘤方式的微卫星不稳定性或NTRK融合。在这一共识中，西班牙医学肿瘤学会（SEOM）和西班牙病理学学会（SEAP）选出的一组专家回顾了这些突变在致癌过程中所起的作用及其临床意义。根据他们的研究结果，提出了一系列建议，以优化这些生物标志物的测定，从而帮助标准化这些肿瘤的诊断和治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista Espanola de Patologia Medicine-Pathology and Forensic Medicine

CiteScore

0.90

自引率

0.00%

发文量

审稿时长

34 days